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Abstract 
The primary study objective was to compare the pharmacokinetics of p.o. terbinafine 
alone to p.o. terbinafine administered with p.o. cimetidine in healthy adult horses. The second 
objective was to assess the pharmacokinetics of terbinafine when administered per rectum in two 
different suspensions at 30 mg/kg to adult horses. Six healthy adult horses were included in this 
crossover study. Plasma terbinafine concentrations were quantified with liquid chromatography 
and mass spectrometry. The half-life (geometric mean) was 8.38 and 10.76 h, for p.o. alone and 
p.o. with cimetidine, respectively. The mean maximum plasma concentrations were 0.291 lg/mL 
at 1.54 h and 0.418 lg/mL at 1.28 h for p.o. alone and p.o. with cimetidine, respectively. 
Terbinafine with cimetidine had an average CMAX 44% higher and the relative F was 153% 
compared p.o. terbinafine alone but was not statistically different (P > 0.05). Terbinafine was 
infrequently detected when administered per rectum in two different suspensions (water or olive 
oil). Minor adverse effects included oral irritation, fever, and colic. All resolved spontaneously. 
More pharmacokinetic studies are indicated assessing drug–drug interactions and using multiple 
dosing intervals to improve our knowledge of effective oral dosing, the potential for drug 
accumulation, and systemic adverse effect of terbinafine in horses. 
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Chapter 1 - Introduction 
Aspergillus sp. cause life-threatening fungal pneumonia, guttural pouch infections, and 
fungal keratitis in horses (Gerard et al. 2006). Fungal infections in horses are clinically 
challenging with regard to limited therapeutic treatments and overwhelming expense for the 
client. The polyene antibiotics and the azoles are the two common classes of antifungal drugs 
used in equine medicine. Unfortunately, options for the oral treatment of fungal infections are 
limited by bioavailability and cost. Itraconazole and voriconazole have activity against 
Aspergillus sp. and are absorbed following oral administration (Davis et al. 2005, 2006), but the 
cost prohibitive nature of most oral antifungal treatments in equine patients limits owner 
compliance, thus worsening the prognosis for fungal diseases in horses.  
Terbinafine (Lamisil ®) is an allylamine antifungal drug approved for use in humans. 
This allylamine is both fungicidal and fungistatic. Terbinafine has antifungal activity alone or in 
multidrug combinations against fungal organisms including Candida albicans, Malassezia 
pachydermatis, Blastomyces dermatitidis, Cryptococcus neoformans, Histoplasma capsulatum, 
Microsporum canis, and Aspergillus species (Shadomy et al., 1985; Goudard et al., 1986; 
Petranyi et al., 1987; Saarikoski et al., 2015).  
Terbinafine is well absorbed after oral administration in small animal species and 
humans, but oral bioavailability in horses is incomplete due to first pass metabolism (Williams et 
al., 2010). Drug–drug interactions with terbinafine have been published (Saarikoski et al., 2015). 
For instance, CYP450 is a hepatic enzyme system that metabolizes terbinafine; alterations in this 
enzyme system have direct effects on subsequent plasma drug concentrations. Cimetidine is a 
CYP450 inhibitor that is occasionally administered in combination with terbinafine in humans. 
2 
This drug interaction results in an increased plasma concentration of terbinafine and a 33% 
decrease in terbinafine clearance in humans (Anonymous, 2015).  
Objective 
The first objective of this study was to compare the pharmacokinetics of oral terbinafine 
alone to p.o. terbinafine administered in combination with p.o. cimetidine in healthy adult horses. 
The second objective of this study was to assess the pharmacokinetics of terbinafine (30 mg/kg) 
when administered per rectum in two different formulations, an aqueous suspension and 
separately in an olive oil suspension to adult horses. 
 
 
. 
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Chapter 2 - Literature Review 
 Aspergillus species 
The most ubiquitous and pathogenic Aspergillus species documented in equine veterinary 
literature are Aspergillus fumigatus, Aspergillus niger, Aspergillus versicolor, Aspergillus flavus, 
and Aspergillus nidulans (Cafarchia C. et al 2012). These opportunistic environmental fungi 
inhabit dead leaves, stored grain, compost piles, hay, and are present in normal equine airways. 
The spores are inhaled by horses and may cause fungal keratitis, guttural pouch mycosis, or 
fungal pneumonia (Gerard et al, 2006). Fungal infections occur in immunocompromised animals 
suffering from endocrinopathies, neoplasia or animals administered prolonged antibiotics and 
corticosteroids. However, in horses the etiology is unclear as to why some horses do and some 
horses do not develop an infection with this common upper respiratory fungus (Cafarchia C. et al 
2012). Clinical signs of Aspergillus sp. infections depend upon the location of the disease. 
Horses with fungal keratitis may present with ptosis, blepharospasm, miosis, and may have a 
concurrent deep stromal abscess (Gerard et al, 2006). Horses with guttural pouch mycosis my 
present for epistaxis, cranial nerve deficits, and/or secondary pneumonia. Also, horses that 
develop fungal pneumonia infection have a cough and are lethargic.  The horses that acquire 
fungal pneumonia infections are commonly hospitalized patients that have been administered 
prolong antibiotics therapies. (Cafarchia C. et al 2012) 
 Diagnosis  
Diagnosis is difficult in the early stages of the disease processes. Diagnosis is based on 
history, clinical signs, and location of the infection. Horses with fungal keratitis Aspergillus sp. 
can be identified with cytology and/or culture. Horses infected with guttural pouch mycosis 
endoscopy is a vital diagnostic to evaluate the upper respiratory tract in the horse. Horses that 
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develop fungal pneumonia radiology is utilized to evaluate the lower respiratory tract. Fungal 
species can be identified with trans-tracheal wash cytology and/or culture (Cafarchia C. et al 
2012; Gerard et al 2006) 
 Treatment 
Treatments of fungal infections include medical and surgical therapies depending on the 
site of infection and the severity of disease. Fungal infections in horses are clinically challenging 
with regards to limited therapeutic treatments and an overwhelming expense for the client. The 
polyene antibiotics and the azoles are the two common classes of antifungal drugs used in equine 
medicine. Unfortunately, options for the oral medical treatment of fungal infections in horses are 
limited by the drug’s bioavailability and cost. The pharmacokinetics of ketoconazole, 
itraconazole, fluconazole, and voriconazole in horses have been studied (Latimer, et al, 2001; 
Davis, et al, 2005; Davis, et al, 2006). Itraconazole and voriconazole have activity against 
Aspergillus sp. and are absorbed following oral administration (Davis et al. 2005, 2006). The 
cost prohibitive nature of most oral antifungal treatments in equine patients limits owner 
compliance thus worsening the prognosis for fungal diseases in horses. 
 Terbinafine antifungal agent 
Terbinafine (Lamisil ®) is an allylamine antifungal drug approved for use in humans. 
This allylamine is both fungicidal and fungistatic. Terbinafine prevents the biosynthesis of 
ergosterol (necessary for cell membrane synthesis) by the inhibition of squalene epoxidase. The 
intracellular accumulation of squalene is cytotoxic (Ryder & Favre, 1997). The depletion of 
ergosterol interferes with cell membrane function and growth. Terbinafine has antifungal activity 
alone or in multi-drug combinations against fungal organisms including: Candida albicans, 
Malassezia pachydermatis, Blastomyces dermatitidis, Cryptococcus neoformans, Histoplasma 
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capsulatum, Microsporum canis, and Aspergillus sp. (Shadomy et al 1985; Goudard et al 1986; 
Petranyi 73 et al 1987; Saarikoski T et al 2015). Terbinafine is well absorbed after oral 
administration in small animal species and humans, but oral bioavailability in horses is 
incomplete due to first pass metabolism (Williams et al 2010). Drug clearance is primarily 
through hepatic biotransformation into numerous inactive metabolites. Williams and colleagues 
found that the terminal half-life after oral administration was 8.1 hours, but the mean maximum 
plasma concentration (CMAX) was only 0.31 μg/ml after a single 20-mg/kg PO dose. The drug 
was well tolerated but did not achieve adequate plasma concentrations to exceed the MIC (0.05- 
2 μg/ml) for relevant Aspergillus spp (Shadomy et al 1985; Goudard et al 1986; Petranyi et al 
1987). Pharmacokinetic drug interactions with terbinafine have been published (Saarikoski T et 
al 2015). For instance, CYP450 is a hepatic enzyme system that metabolizes terbinafine; 
alterations in this enzyme system have direct affects on subsequent plasma drug concentrations. 
Cimetidine is a CYP450 inhibitor that is frequently administered in combination with terbinafine 
in humans. This drug interaction results in an increased plasma concentration of terbinafine and a 
33% decrease in terbinafine clearance (Anonymous, 2015). The veterinary literature on 
terbinafine administered alone or in antifungal drug combinations has been shown to be 
clinically effective and well tolerated in domesticated and non-domesticated animals. However, 
investigations testing application of terbinafine in horses is limited. Williams et al 2010 
investigated terbinafine absorption in horses when administered a single 20-mg/kg oral dose over 
24 hours. A separate report indicated that terbinafine administered to horses at 30-mg/kg PO for 
up to 14 days 96 resulted in no observed adverse effects. There are no studies that examined the 
pharmacokinetics of terbinafine in horses when administered alternate routes aimed at achieving 
MICs effective against Aspergillus sp.  
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Chapter 3 - Material and Methods 
 Animals  
The Institutional Animal Care and Use Committee at Kansas State University approved 
the study. This crossover systematically randomized study used six adult healthy horses, ranging 
in age and weight from 8 to 17 years and 490 to 620 kg, respectively. The breeds included three 
Quarter Horses, one Paint, one Trakehner, and one Thoroughbred. Three of the horses were 
mares, and three were geldings. The horses were acclimated to the indoor stalls the day prior to 
drug administration. Horses were offered brome or prairie hay and water ad libitum throughout 
the study, consistent with their routine roughage diet. Horses were fed their routine ration 
between 2 and 3 pounds of pelleted feed, twice daily. Prior to study enrollment, a physical 
examination and complete blood count were conducted and were found to be within species- and 
age-specific reference intervals. Animals were monitored for 24 h after drug administration. 
 Drug dosing treatments  
The study consisted of four treatments using terbinafine tablets (terbinafine 
hydrochloride, 250 mg tablets; Liconsa, Guadalajara, Spain). Terbinafine was administered p.o. 
(30 mg/kg) to all six horses; terbinafine was administered p.o. (30 mg/kg) to all six horses 2 h 
after 30 mg/kg p.o. cimetidine (cimetidine, 400 mg tablet; Novopharm Limited, Toronto, ON, 
Canada); three randomly chosen horses received terbinafine tablets (30 mg/kg) crushed and 
suspended in water per rectum, and three horses received terbinafine tablets (30 mg/kg) crushed 
and suspended in olive oil per rectum. For the oral administration, both terbinafine and 
cimetidine tablets were crushed individually with a mortar and pestle and were combined with 
water and molasses to make a paste-like consistency. Two 35- cc dosing syringes were used to 
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administer total drug volume. The tablet total administered to each horse was rounded to the 
nearest whole tablet, regardless of route. At least 7 days was allowed between each treatment as 
a washout period. 
 Blood sampling for plasma analysis of terbinafine  
Intravenous jugular catheters were aseptically placed for blood collection. Whole blood (9 mL) 
was collected and discarded prior to sample collection to ensure that samples were not 
contaminated with heparinized saline. Whole blood (9 mL) was collected at each time point 
followed by the catheter being flushed with 12 mL of heparinized (4 IU/mL) saline. The whole 
blood was transferred into tubes containing lithium heparin at times 0 (prior to drug 
administration), 10 min, 20 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h after drug 
administration. Blood was kept on ice until separation by centrifugation. Blood was centrifuged 
for 15 min at 30009 g; plasma was separated and stored frozen at 70 °C until analysis with 
LC/MS/MS.  
 Plasma concentrations of terbinafine  
Plasma concentrations of terbinafine were measured with ultraperformance liquid 
chromatography (Acquity UPLC, Waters, Milford MA, USA) with triple quadrupole mass 
spectrometry (TQD, Waters) UPLC/MS. The qualifying and quantifying ions for terbinafine 
(Sigma-Aldrich, St Louis, MO, USA) were mass/charge (m/z) 292.27 and 140.994, respectively. 
The qualifying and quantifying ions for the internal standard tolnaftate (Sigma-Aldrich) were 
m/z 308.26 and 148.027, respectively. Plasma standards were prepared in untreated equine 
plasma by adding standard solution in 50% methanol to untreated plasma to not exceed 10% 
spiking solution per standard. Standard curves achieved a linear range 0.005– 1 lg/mL with 0.005 
lg/mL being the lower limit of quantification. Daily runs were accepted if the plasma standards 
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and quality control samples were within 15% of the actual concentration. Plasma standards, 
quality control samples, and plasma samples were extracted identically using pass-through 
sample preparation to remove phospholipids and proteins (Ostro Pass-through Sample plates, 
Waters). Plasma, 50 lL, was added to the plates, followed by 150 lL acetonitrile with 1% formic 
acid and 500 ng/mL tolnaftate, which was mixed and then the precipitate passed through the 
sample plates. The injection volume was 0.5 lL. A C18 column (CSH C18+, 50 9 2.1 mm, 1.7 lm 
pore size, Waters, Milford, MA, USA) maintained at 55 °C was used for separation. The mobile 
phase consisted of A: 0.2% formic acid in deionized water and B: acetonitrile at a flow rate of 
0.8 mL/min. The mobile phase gradient started at 70% A with a linear gradient to 100% B at 0.3 
min, which was held until 0.89 min with a step to 70% A at 0.9 min with a total run time of 1.5 
min. The accuracy of the assay was determined on replicates of five quality control samples in 
pooled untreated equine plasma fortified with 0.005, 0.05, and 1 lg/mL terbinafine and were 
within 1, 1, and 4% of expected concentrations, respectively. The coefficient of variation was 
determined on replicates of five quality control samples at 0.005, 0.05, and 1 lg/mL and were 6, 
8, and 4%, respectively. 
 Pharmacokinetics and statistical analysis  
Noncompartmental pharmacokinetic analysis was completed using computer software 
(Phoenix 64, Certara, Princeton, NJ, USA). The pharmacokinetic values for each individual were 
calculated, and the geometric mean and range (minimum– maximum) are reported (Julious & 
Debarnot, 2000). The following pharmacokinetic parameters were calculated: AUC0-INF = area 
under the curve extrapolated to infinity using the linear trapezoidal method; AUCExtrap = 
percent of the AUC extrapolated to infinity; AUC0-LAST = area under the curve from time 0 to 
the last concentration above the lower analytical limit of quantification; Cl/F = clearance per 
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fraction of the dose absorbed; T½ = terminal half-life; kz = terminal rate constant; MRT = mean 
residence time extrapolated to infinity; Vz/F = volume of distribution (area method) per fraction 
of the dose absorbed. The CMAX = maximum plasma concentrations and TMAX = time of 
CMAX were determined directly from the data. The relative F = fraction of the dose of 
terbinafine with cimetidine absorbed relative to oral terbinafine alone was calculated with the 
following equation:  
𝑇𝑒𝑟𝑏𝑖𝑛𝑎𝑓𝑖𝑛𝑒 𝐴𝑈𝐶 𝑤𝑖𝑡ℎ 𝐶𝑖𝑚𝑒𝑡𝑑𝑖𝑖𝑛𝑒
𝑇𝑒𝑟𝑏𝑖𝑛𝑎𝑓𝑖𝑛𝑒 𝐴𝑈𝐶 𝑎𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑒𝑟𝑒𝑑 𝑎𝑙𝑜𝑛𝑒
 
 
Statistical analysis of the pharmacokinetic data was performed with computer software 
(Sigma Plot 12.5, Systat, Chicago IL, USA) using Mann–Whitney rank-sum analysis (Powers, 
1990). The significance was set at P < 0.05. The pharmacokinetic parameters of p.o. terbinafine 
administered alone were compared to the pharmacokinetic data of p.o. terbinafine administered 
concurrently with p.o. cimetidine. One horse each in the terbinafine (horse #1, 61%) and 
terbinafine with cimetidine (horse #2, 47%) had excessive extrapolation of the AUC, which 
could lead to inaccurate estimates of some pharmacokinetic parameters. Therefore, the only PK 
parameters reported and statistically assessed from those horses were the AUC0-LAST, CMAX, 
and TMAX. The relative fraction of the dose absorbed was calculated in four horses as horse #1 
(terbinafine) and horse #2 (terbinafine with cimetidine) had excessive extrapolation of the 
AUC0-INF. Per rectum pharmacokinetic analysis was not conducted for either suspension due to 
the low number of plasma concentrations exceeding the lower limit of analytical quantification. 
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Chapter 4 - Results 
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Figure 1.4 The mean and standard deviation plasma concentration of terbinafine following 
oral terbinafine administered alone (PO) and combination of terbinafine orally with 
cimetidine (PO-CIM) 
 
The mean maximum plasma concentrations of p.o. terbinafine administered alone and 
terbinafine with cimetidine were 0.291 lg/mL at 1.54 h and 0.417 lg/mL at 1.28 h, respectively.  
 
 
 
 
 
11 
 Oral Terbinafine Oral Terbinafine with Cimetidine 
Parameter Units N Mean Range N Mean Range P-Value 
AUC Extrap % 5 10.4 7.3 - 14.5 5 14.1 10.1 - 18.0 0.222 
AUC hr*ug/mL 5 1.66 1.18 - 2.38 5 1.943 0.935 - 3.73 0.548 
AUC0-LAST hr*ug/mL 6 1.39 0.992 – 2.20 6 1.81 0.788 - 3.355 0.310 
Cl/F mL/min/kg 5 0.300 0.211 - 0.420 5 0.257 0.134  -0.539 0.549 
C MAX ug/mL 6 0.291 0.176 - 0.510 6 0.418 0.156 - 0.701 0.156 
T ½  hr 5 8.38 5.98 - 10.88 5 10.76 8.66 - 13.58 0.151 
λz 1/hr 5 0.083 0.064 - 0.116 5 0.0644 0.0510 - 0.080 0.095 
MRT hr 5 9.74 8.69 - 11.11 5 10.76 8.68 - 12.50 0.548 
T MAX hr 6 1.54 1.00 - 4.00 6 1.28 1.00 - 2.00 0.699 
Vz/F L/kg 5 0.218 0.109 - 0.370 5 0.239 0.106 - 0.507 1.000 
Relative F  %  N/A N/A 4 153 108 - 257 N/A 
Table 1.4 Pharmacokinetics of oral terbinafine and oral terbinafine administered 
concurrently with oral cimetidine (geometric mean and ranges). 
AUC Extrap = percent of the AUC extrapolated to infinity; AUC0-LAST = area under the curve 
from time 0 to the last concentration above the lower analytical limit of quantification; AUC= 
AUC extrapolated to infinity; Cl/F = clearance per fraction of the dose absorbed; C MAX = 
maximum plasma concentrations; T ½ = terminal half-life; λz = terminal rate constant; MRT = 
mean residence time extrapolated to infinity; T MAX = time of C MAX; Vz/F = volume of 
distribution (area method) per fraction of the dose absorbed; relative % F = fraction of the dose 
absorbed relative to oral terbinafine. The P value comparing oral terbinafine to oral terbinafine 
concurrently with oral cimetidine was calculated using the Mann-Whitney Rank sum test. 
Terbinafine with cimetidine achieved an average 44% higher CMAX and 30% higher 
AUC0-LAST compared to oral terbinafine alone. The mean relative F of terbinafine with 
cimetidine was 153% using AUC0-INF. However, these parameters were not statistically 
different (P > 0.05). No statistical difference in any pharmacokinetic parameter was found 
between the two treatment protocols. The highest measured concentration of terbinafine after per 
rectum administration of terbinafine suspended in water to three horses was 0.059 lg/mL. The 
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highest measured concentration of terbinafine after per rectum administration of terbinafine 
suspended in olive oil to three horses was 0.013 lg/mL. Most of the plasma concentrations after 
per rectum administration of terbinafine were below the analytical lower limit of quantification 
(0.005 lg/mL) precluding pharmacokinetic analysis. 
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Chapter 5 - Discussion 
To the authors’ knowledge, this is the first terbinafine pharmacokinetic report of a 30-
mg/kg oral dose and terbinafine combined with cimetidine. Additionally, this is the first report of 
terbinafine administered per rectum in adult horses. The pharmacodynamics of terbinafine 
suggests clinical efficiency against Aspergillus spp, Fusarium spp., Paecilomyces spp., Candida 
albicans, dematiaceous molds, and Scedosporium prolificans, but efficacy studies are needed to 
confirm clinical efficacy (Shadomy et al 1985; Goudard et al, 1986; Petranyi et al 1987). The 
reported MIC for Aspergillus species are as follows: Aspergillus fumigatus MIC range – 0.2-5 
ug/ml, Aspergillus flavus MIC range 0.02-0.05 ug/ml, and Aspergillus niger MIC range 0.02-0.2 
ug/ml.  Aspergillus spp are commonly treated with itraconazole, clotrimazole topically, 
fluconazole, voriconazole, and amphotericin B, but the in vitro activity of terbinafine suggests it 
could be a reasonable treatment choice.  
The single 30 mg/kg oral dose, 30 mg/kg PO in combination with PO cimetidine, and 
terbinafine 30 mg/kg per rectum all failed to achieve plasma concentrations exceeding the reported 
MIC levels required for all Aspergillus spp. However, plasma concentrations exceeding the MIC 
ranges for Aspergillus niger and A. flavus were achieved, but the MIC ranges were not for equine 
isolates so it is unclear if the MIC for equine isolates are within similar ranges. Multiple dose 
administration could result in drug accumulation and achieve the MIC requirements of all 
Aspergillus spp. However, further studies are needed to document the multiple dose 
pharmacokinetics of terbinafine in horses. 
A study by Cavalherio et al (2009) observed a synergistic pharmacodynamic interaction of 
terbinafine when combined with other antifungal agents. That investigation concluded 
combination of terbinafine with fluconazole achieved the highest terbinafine plasma 
14 
concentrations when compared to the other protocols. Therefore, the therapeutic efficacy of 
terbinafine may be enhanced not only by pharmacokinetic interactions, but pharmacodynamic 
interactions in the horse. However further studies are needed to assess the efficacy and safety of 
drug combinations in horses. 
Although in the current study the combination of terbinafine with cimetidine resulted in a 
higher plasma concentration (CMAX and AUC’s) than terbinafine administered alone, this 
difference did not reach statistical significance.  The increase in plasma concentration may be due 
to the inhibitory effects of cimetidine acting on the hepatic metabolizing enzyme system. An 
interaction of similar magnitude is documented in humans administered terbinafine with 
cimetidine resulting in a 33% decrease in clearance which should produce a 33% increase in AUC 
(Anonymous, 2015). The FDA defines a weak inhibitor resulting in a 25-100% increase in the 
AUC of the substrate. Based on the results of this study, cimetidine can be considered a weak 
inhibitor of terbinafine in the horse. If moderate (100-500% increase in terbinafine AUC) or strong 
inhibitors (>500% increase in terbinafine AUC) of terbinafine in horses are found, then the 
potential clinical utility of terbinafine would be markedly increased.   
Per rectum drug administration had low plasma concentrations when compared to the oral 
route. The rational of using the per rectal route in horses is aimed at reducing adverse effects 
observed with oral administration while in addition, potentially improving systemic drug exposure 
due to reduced first pass metabolism. Low rectal bioavailability may have been due to poor water 
solubility of terbinafine, pre-systemic metabolism, or interactions with rectal contents. A pilot 
study using three horses each assessed terbinafine suspended in water and in olive oil at a doses of 
30 mg/kg terbinafine. However, data from the pilot study using terbinafine suspended with olive 
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oil revealed poor rectal absorption, similar to the water suspension. Based on this data, terbinafine 
administered orally produced superior systemic drug exposure compared to per rectal. 
Adverse affects demonstrated by the horses in this study included asymptomatic fever and 
oral irritation. This elevation in temperature may have been due to environmental causes in the 
barn, thermometer error, or systemic drug adverse effect. Oral adverse affects observed in this 
report correlated with the previous study by Williams et al 2010. In our study the primary 
investigator found mixing crushed terbinafine tablets with water made a paste consistency.  This 
suspension may have caused the minor oral adverse effects observed in three horses.  
Limitations of this study include only a single terbinafine dose was administered, so no 
conclusions can be made on multiple dosing protocols in horses at this time. A healthy population 
of adult horses was used in this investigation, so conclusions of drug plasma concentrations in sick 
individuals or foals cannot be concluded.  The horse’s liver and kidney values were not evaluated 
after the terbinafine administration so no conclusions could be made on systemic adverse effects, 
however clinical examination of all horses was normal throughout the study duration. Relative 
bioavailability was calculated due to the lack IV drug formulation to obtain the true percent 
bioavailability.  The number of horses investigated in this study is a limitation when determining 
a statistical difference among the drug protocols in question due to the observed variability. In 
conclusion, orally dosed terbinafine with cimetidine did not produce severe adverse effects when 
a single dose was administered to the adult horse. Orally dosed terbinafine compared to per rectal 
is superior with regard to drug plasma concentration. Potential oral irritation, palatability, or fever 
should be considered adverse effects when administering terbinafine to horses.  More 
pharmacokinetic studies are indicated to determine the safest, highest, and most cost effective 
terbinafine dose administered orally alone and/or in combination with cimetidine in adult horses. 
16 
Indications for PK studies using multiple dosing intervals will improve our knowledge of a 
potential residual drug accumulation and potential systemic side effects in horses. Further 
randomized case control studies are indicated to assess the clinical efficacy of terbinafine for the 
treatment of fungal diseases in adult horses.  
 
 
 
  
17 
References  
Anonymous (2015) Lamisil – Highlights of prescribing information. Novartis Pharmaceuticals 
Corporation, East Hanover, NJ 
 
Cafarchia C, Paradies R, Figueredo L, Padalino B, Greco F, Greco G, Otranto D. (2012) A case 
of equine aspergillosis: A novel sampling procedure for diagnosis. Journal of Equine Veterinary 
Science, 32, 634-637. 
 
Cavalheiro AS, Maboni G, de Azevedo MI, Argenta JS, Pereira DI, Spader TB, Alves SH, 
Santurio JM. (2009) In Vitro activity of terbinafine combined with caspofungin and azoles 
against Pythium insidiosum. Antimicrobial Agents and Chemotherapeutics, 53, 2136-2138. 
 
Davis JL, Salmon JH, Papich MG. Pharmacokinetics and tissue distribution of itraconazole after 
oral and intravenous administration to horses. (2005) American Journal of Veterinary Research, 
66, 1694-1701. 
 
Davis JL, Salmon JH, Papich MG.  (2006) Pharmacokinetics of voriconazole after oral and 
intravenous administration to horses. American Journal of Veterinary Research, 67, 1070-1075. 
 
Gerard MP, Wotman KL, Komáromy AM. Infections of the head and ocular structures in the 
horse. (2006) Veterinary Clininics of North America: Equine Practice, 22, 591-631 
 
Goudard M, Buffard Y, Ferrari H, Regli P. (1986) [In vitro spectrum of action of a 
new antifungal derivative of naftifin: terbinafin (SF 86-327)]. Pathologie Biologie, 34, 680-683. 
 
Julious SA, Debarnot CA. (2000) Why are pharmacokinetic data summarized by arithmetic 
means? Journal of Biopharmaceutical Statistics, 10, 55-71. 
 
Latimer FG, Colitz CM, Campbell NB, Papich MG. (2001) Pharmacokinetics of fluconazole 
following intravenous and oral administration and body fluid concentrations of fluconazole 
18 
following repeated oral dosing in horses. American Journal of Veterinary Research, 62, 1606-
1611. 
 
Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative 
terbinafine in vitro. Antimicrob Agents Chemother. 1987. 31: 1365-1368. 
 
Powers J. (1990) Statistical analysis of pharmacokinetic data. Journal of Vetetinary Pharacology 
and Therapeutics, 13, 113-120. 
 
Ryder, N.S. and B. Favre. Antifungal activity and mechanism of action of terbinafine. Rev 
Contemp Pharmacother 1997. 8:275-287  
 
Saarikoski T, Saari TI, Hagelberg NM, Backman JT, Neuvonen PJ, Scheinin M, 
Olkkola KT, Laine K. (2015) Effects of terbinafine and itraconazole on the 
pharmacokinetics of orally administered tramadol. European Journal of Clinical Pharmacology, 
71, 321-327. 
 
Shadomy S, Espinel-Ingroff A, Gebhart RJ. (1985) In-vitro studies with SF 86-327, a 
new orally active allylamine derivative. Sabouraudia, 23, 125-132. 
 
Williams MM, Davis EG, Kukanich B. Pharmacokinetics of oral terbinafine in horses and 
Greyhound dogs. Journal of Vetetinary Pharacology and Therapeutics. 2010 Jun;34(3):232-7 
 
 
 
 
